8-K - Aspire Biopharma Holdings, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Securities Issuance

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement On January 26, 2026, Aspire Biopharma Holdings, Inc. (the “Company”), entered into a Securities Purchase Agreement (t

Material Agreement

$2.2M$2.0M$8.0M

Source Document

3.02

Unregistered Sales of Equity Securities See Item 1.01 above. Item 9.01 Financial Statements and Exhibits. d) Exhibits Exhibit No. Description 10.1 Form of Secur

Securities Issuance

Exhibits (3)

10.1

EX-10.1

10.2

EX-10.2

8-K